(:SURP)

Mar 01, 2017 11:57 am ET
Tamarack Biotics obtains GRAS status for TruActive NF, further validating SurePure Technology
NEW YORK, March 1, 2017 /PRNewswire/ -- SurePure, Inc. (OTCQB: SURP) a global leader in liquid photopurification, announced today that Tamarack Biotics has completed a self-affirmed "Generally Recognized as Safe" (GRAS) approval for its TruActive™ NF product. 
Dec 01, 2016 05:53 pm ET
Tamarack Biotics Signals Intent To Implement SurePure Technology
NEW YORK, Dec. 1, 2016 /PRNewswire/ -- SurePure, Inc. (OTCQB: SURP) a global leader in liquid photopurification, announced today that the Company has concluded an agreement with Tamarack Biotics under which Tamarack Biotics has the right for a 90-day period to acquire units of the Company's patented photopurification technology with an invoice value of approximately USD 3.7 million. 
Oct 10, 2016 09:00 am ET
SurePure Granted Membership of Social Stock Exchange
NEW YORK, Oct 10, 2016 /PRNewswire/ -- SurePure, Inc. (OTCQB: SURP), a global leader in liquid photopurification, announced today that it has been approved as a member of the Social Stock Exchange following the ratification of its impact report by the Independent Admissions Panel.
Aug 09, 2016 01:01 pm ET
SurePure Announces Results for the Quarter ended June 30, 2016 with the Filing of Its Quarterly Report on Form 10-Q
NEW YORK, Aug. 9, 2016 /PRNewswire/ -- SurePure, Inc. (OTCQB: SURP), a global leader in liquid photopurification, announced today that the Company has filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 with the U.S. Securities and Exchange Commission (SEC).
Apr 07, 2016 11:18 am ET
SurePure Technology Instrumental in Clinical Trial
NEW YORK, April 7, 2016 /PRNewswire/ -- SurePure, Inc. (OTCBB: SURP) a global leader in liquid photopurification, announced today that the Company's patented photopurification technology has been used to produce key research samples for an upcoming clinical trial.  This trial is expected to demonstrate that SurePure's technology, which enables immune active proteins to remain undamaged, will stimulate greater vaccine response in the elderly.  Tamarack Biotics and UC Davis are jointly conducting the clinical trial in California. 

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.